Therapeutic Plasma Exchange for Autoimmune Disease
TPE is one of the most established treatments in apheresis medicine — recognized as first-line therapy for multiple autoimmune conditions by the American Society for Apheresis.
Autoimmune diseases occur when the immune system produces antibodies that attack the body's own tissues. These pathogenic autoantibodies, along with inflammatory immune complexes and cytokines, circulate in the blood — and that's exactly where therapeutic plasma exchange intervenes. By removing the plasma that carries these disease-driving factors and replacing it with clean albumin solution, TPE can rapidly reduce disease activity and support recovery.
Why TPE Works for Autoimmune Disease
The Autoimmune Cycle
In autoimmune disease, the immune system generates antibodies (autoantibodies) that mistakenly target the body's own tissues — nerve cells, muscle receptors, blood vessel walls, or organs depending on the condition. These autoantibodies circulate in the blood, continuously reaching their targets and sustaining the attack. Alongside them, inflammatory cytokines and immune complexes amplify the damage, creating a self-perpetuating cycle of immune activation and tissue destruction.
How TPE Breaks the Cycle
Therapeutic plasma exchange physically removes these pathogenic factors from circulation. In a single procedure, a full plasma volume exchange can remove approximately 60–70% of circulating autoantibodies, immune complexes, complement factors, and inflammatory cytokines. By rapidly reducing the concentration of disease-driving molecules, TPE can halt or slow the immune attack, giving the body — and concurrent immunosuppressive therapies — room to work.
The Albumin Advantage
The replacement fluid — 5% albumin solution — is immunologically neutral. It does not contain the autoantibodies or inflammatory mediators that were removed. It does provide physiologic oncotic support and carries inherent anti-inflammatory and antioxidant properties. The result is a cleaner immunological environment that supports immune rebalancing.
Complementing Other Therapies
TPE is most effective as part of a comprehensive treatment approach. It works alongside immunosuppressive medications, corticosteroids, and targeted biologic therapies. While these medications take days to weeks to reach full effect, TPE provides immediate reduction in disease-driving factors — making it particularly valuable during acute flares, rapid deterioration, or as a bridge to longer-term immunotherapy.
Conditions Treated with Therapeutic Plasma Exchange
The American Society for Apheresis (ASFA) publishes evidence-based guidelines that categorize TPE indications by the strength of clinical evidence. Category I indicates TPE is a standard first-line therapy. Category II indicates TPE is well-established as second-line or supportive treatment. Many autoimmune conditions carry Category I or II designations — reflecting decades of clinical evidence and thousands of patients treated.
Many Category I conditions — such as myasthenic crisis, acute GBS, and TTP — present as medical emergencies that are treated in hospital-based apheresis units. At Global Apheresis, Dr. Green focuses on outpatient autoimmune applications: chronic maintenance TPE for conditions like CIDP and refractory myasthenia gravis, management of autoimmune conditions that don't require inpatient care, and ongoing support for patients whose acute hospital-based treatment is complete but who benefit from continued TPE. If your condition is emergent or urgent, please call 911 or go to your nearest emergency room.
Myasthenia Gravis (MG)
An autoimmune condition in which antibodies attack acetylcholine receptors at the neuromuscular junction, causing muscle weakness and fatigue. TPE removes anti-AChR antibodies from circulation, providing rapid improvement — particularly critical during myasthenic crisis, where respiratory muscles are affected.
Guillain-Barré Syndrome (GBS)
An acute autoimmune attack on the peripheral nervous system, causing progressive weakness that can lead to paralysis. TPE removes the autoantibodies driving nerve damage and is one of two first-line treatments (alongside IVIG). Most effective when initiated early in the disease course.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The chronic counterpart to GBS — an ongoing autoimmune attack on peripheral nerve myelin causing progressive weakness and sensory changes. TPE removes circulating autoantibodies and inflammatory mediators that sustain the demyelination.
Neuromyelitis Optica Spectrum Disorder (NMOSD)
A severe autoimmune condition affecting the optic nerves and spinal cord, often caused by anti-aquaporin-4 antibodies. TPE removes these pathogenic antibodies and is used during acute attacks, particularly when steroid treatment is insufficient.
Anti-NMDA Receptor Encephalitis
An autoimmune encephalitis caused by antibodies against NMDA receptors in the brain, presenting with psychiatric symptoms, seizures, and movement disorders. TPE removes the pathogenic antibodies from circulation.
Thrombotic Thrombocytopenic Purpura (TTP)
A life-threatening condition in which autoantibodies against ADAMTS13 cause widespread blood clotting in small vessels. TPE is the definitive treatment — removing the autoantibodies and replacing ADAMTS13.
Multiple Sclerosis (MS) — Acute Attacks
For acute MS relapses that do not respond adequately to high-dose corticosteroids, TPE is an established second-line treatment. It removes inflammatory mediators and autoantibodies contributing to the acute demyelinating attack.
Systemic Lupus Erythematosus (SLE)
In severe lupus — particularly with renal involvement (lupus nephritis) or catastrophic presentations — TPE removes autoantibodies (including anti-dsDNA), immune complexes, and complement-activating factors.
Systemic Sclerosis (Scleroderma)
An autoimmune condition causing fibrosis of the skin and internal organs. TPE removes circulating autoantibodies and inflammatory mediators that drive the fibrotic process.
TPE is recognized for numerous additional autoimmune and inflammatory conditions beyond those listed above, including autoimmune hemolytic anemia, pemphigus vulgaris, vasculitis syndromes, and others. ASFA guidelines categorize over 80 conditions where apheresis may be indicated. Dr. Green evaluates each patient's specific condition and clinical situation to determine whether TPE is appropriate.
Clinical Experience in Autoimmune Apheresis
Dr. Green's training in therapeutic apheresis at UT Southwestern Medical Center, under Dr. Ravi Sarode, provided deep experience in autoimmune indications. His residency included extensive hands-on management of TPE for conditions ranging from TTP and myasthenia gravis to GBS and systemic sclerosis.
His published research touches directly on autoimmune applications:
- Optimizing caplacizumab dosing in immune-mediated TTP (Yates, Green, Sarode et al., Blood Vessels, Thrombosis & Hemostasis, 2024)
- TPE response in systemic sclerosis (ASFA 2023 poster)
- TPE in hyperviscosity syndrome associated with juvenile rheumatoid arthritis (Green et al., J Clin Apheresis, 2021)
This clinical and research experience informs the autoimmune protocols used at Global Apheresis today.
What Treatment Looks Like
Acute Flares
When autoimmune disease flares — increased weakness in myasthenia gravis, worsening symptoms in CIDP, or a lupus flare — a focused series of 5–7 TPE sessions over 1–2 weeks can rapidly reduce circulating autoantibodies and bring disease activity under control. These sessions are coordinated with your neurologist or rheumatologist and are appropriate once any acute emergency has been stabilized.
Chronic Management
For chronic conditions like CIDP or refractory autoimmune disease, TPE may be used as ongoing maintenance — periodic sessions to keep autoantibody levels suppressed and disease activity controlled. Frequency is tailored to your clinical response.
Working With Your Team
TPE for autoimmune conditions is most effective as part of a coordinated treatment plan. Dr. Green works alongside your existing specialists — neurologists, rheumatologists, hematologists — to integrate TPE into your overall management. He does not replace your primary specialist; he adds the apheresis expertise.
For Patients Traveling
Flexible scheduling can be arranged for patients coming to Mill Valley from outside the Bay Area. Contact our office to discuss logistics for out-of-area treatment.
Discuss Your Condition
If you've been diagnosed with an autoimmune condition and want to understand whether therapeutic plasma exchange could be part of your treatment plan, schedule a complimentary discovery call with Dr. Green.